The Claim
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a mean loss of 1.51 kg of lean body mass in adults with obesity or type 2 diabetes undergoing weight loss, and this loss constitutes approximately 31% of total weight reduction.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity or type 2 diabetes who are losing weight using GLP-1 receptor agonists, an average of 1.51 kilograms of lean body mass is lost, making up about 31% of the total weight lost.
See the scientific wording
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a mean loss of 1.51 kg of lean body mass in adults with obesity or type 2 diabetes undergoing weight loss, with this loss accounting for approximately 31% of total weight reduction, suggesting that lean mass depletion is a consistent component of pharmacologically induced weight loss with these agents.
GLP-1 receptor agonists signal the brain to reduce hunger and food intake, causing the body to burn more energy than it takes in. To make up for the energy shortfall, the body breaks down muscle tissue to extract amino acids, which are used to produce glucose in the liver and kidneys. This process drains lean mass over time, resulting in measurable loss of muscle and other lean tissues.
What the research says
1 studyThis study found that when people with obesity or diabetes lose weight using GLP-1RA drugs, they also lose about 1.5 kilograms of muscle and other lean tissue, which makes up roughly one-third of their total weight loss — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.